Trevi Therapeutics, Inc. TRVI Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Trevi Therapeutics, Inc. (TRVI) reported valuation allowance, deferred tax asset, increase (decrease), amount of $2.8M in Q4 2025.
- How has Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount decreased by 13.2% year-over-year, from $3.23M to $2.8M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount has grown at a 3.1% compound annual growth rate (CAGR), from $9.9M to $11.2M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- This metric tracks the net change in the valuation allowance established against deferred tax assets. An increase in the allowance suggests that the company is less confident in its ability to utilize tax assets, such as net operating losses, in the future. It serves as a proxy for management's outlook on future taxable earnings.